What is MohsTEK?
MohsTEK operates as a specialized provider of laboratory services, with a core competency in histopathology and Mohs surgery support. By deploying a mobile service architecture, the company addresses critical gaps in biopsy preparation and melanoma detection, ensuring that healthcare providers receive rapid, high-fidelity diagnostic reports. Their integration of skilled technical staff and in-house pathology expertise allows for a streamlined workflow that enhances patient outcomes while maintaining rigorous quality standards in the competitive medical laboratory landscape.
How much funding has MohsTEK raised?
MohsTEK has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in MohsTEK
PPP
Public-Private Partnership
What's next for MohsTEK?
The infusion of capital from this late-stage financing round provides MohsTEK with the necessary resources to accelerate its market penetration and enhance its diagnostic infrastructure. Strategic priorities likely include the expansion of its mobile laboratory fleet, the integration of advanced digital pathology tools, and the strengthening of clinical partnerships. As the company transitions into this growth phase, the focus will remain on operational efficiency and the scaling of its specialized service delivery model to meet the increasing demand for precise, on-site dermatological diagnostics.
See full MohsTEK company page
